To: semi_infinite who wrote (889 ) 7/20/2018 1:19:10 PM From: tuck 1 RecommendationRecommended By
Read Replies (1) | Respond to It's possible that, because of Reata's (RETA) surrogate endpoint, the trial will meet that endpoint. It is less likely to be approved. If there's an AdComm, forget it. And even if it sneaked through that, what nephrologist would prescribe it given the long term risk for patients that are likely to be long term patients? PGS suggests patience required before this one implodes, and he may be right. It's been a short squeezing rocket lately. The only clinical or regulatory clarity I've seen lately was Orphan Designation for Freidrich's Ataxia. Hardly justifies the 150% rise since you posted that paper. I've built a position, currently somewhat under water (made a little on a RETA short earlier this year). But I am prepared to be patient. Others see the problem: short interest is huge. But heavily shorted biotechs are going bananas these days.
